Abstract
The natural tetracyclic schweinfurthins are potent and selective inhibitors of cell growth in the National Cancer Institute’s 60-cell line screen. Most of the natural schweinfurthins display unique and potent activity in the 60 cell-line screen of the National Cancer Institute. At this time, the mechanism or cellular target that underlies this activity has not yet been identified, and efforts to illuminate the schweinfurthins’ mode of action would benefit from development of potent fluorescent analogues that could be readily visualized within cells. This report describes the synthesis of fluorescent analogues of schweinfurthins B and F, and demonstrates that these compounds retain the potent and differentially toxic activities against select human cancer cells that are characteristic of the natural schweinfurthins. In addition, the synthesis of control compounds that maintain parallel fluorescent properties, but lack the potent activity of the natural schweinfurthin is described. Use of fluorescence microscopy shows differences between the localization of the active and re latively inactive schweinfurthin analogues. The active compounds localize in peripheral puncta which may identify the site (or sites) of activity.
1. Introduction
Natural products have been a significant source of drug leads in oncology.1 Indeed several commonly used anti-cancer agents are themselves natural products or are the result of drug development programs based upon a natural product. In some instances, natural products have identified a novel target or mechanism of action that is useful in treating human cancer. One such agent is paclitaxel, which was found to stabilize micro-tubules causing cell cycle arrest just prior to mitosis.2 From this perspective, the discovery of the schweinfurthins and their potent anti-cancer activity at the National Cancer Institute (NCI) may offer a similar opportunity for discovery of a novel drug target and/or mechanism of action.3 Nine compounds are now part of the natural family, including schweinfurthin A–H and vedelianin (Figure 1).4-6 Those that contain a hexahydroxanthene substructure, such as schweinfurthin A (1) and B (2), were found to have potent activity in the NCI 60 cell-line screen. Perhaps of even greater importance, the pattern of activity against the 60 cell lines indicated a potentially novel molecular target or mechanism of activity.7,8 Due to the scarcity of the natural schweinfurthins, we have had an ongoing program aimed at synthesis of natural schweinfurthins and preparation of analogues. This effort has culminated in the reported syntheses of schweinfurthin B (2),9 C (3),10 E (6),9 F (7),11 and G (8),12 as well as the lead compound 3-deoxyschweinfurthin B (3dSB, 10) and more than 50 other analogues.14-19
Figure 1.
Structures of the natural schweinfurthins and selected analogues.
Recently the bis-stilbene 11 was prepared as a fluorescent analog of 3dSB (10), with the hope that this probe would aid in elucidation of the mechanism of action of these natural products.16 Unfortunately, the fluorescence emission maximum of this compound (416 nm) displayed significant overlap with autofluorescence of the SF – 295 human-derived glioma cell line, and the compound demonstrated a rapid loss of fluorescence upon irradiation. To overcome these limitations and improve the fluorescent charact eristics of potential probes, further synthetic efforts based on this core structure have been undertaken. Here the design, synthesis, and initial biological results of these studies will be reported, along with preparation of some related compounds with similar fluorescence properties and less potent biological activity to serve as controls.
2. Synthesis
While the stilbene 11 did show improved fluorescence properties over the parent 3dSB (10), identification of a related compound with an emission maximum further shifted to lower energy and more resistant to photo-bleaching would be attractive. Placement of an E-ring substituent on the para position would be expected to allow transmission of electronic effects throughout the stilbene system. Therefore, to increase the Stokes shift and secure an emission maximum further to the red, the m-phenol was replaced with a p-nitro group. This substitution was based upon the hypothesis that an effective electron withdrawing group across the bis-stilbene system would complement the electron donatin g C-ring ethers and improve the fluorescent properties of the compound.20, 21
Synthesis of compound 19 began with the known aldehyde 12 (Scheme 1).16 Treatment with p-nitrobenzyl phosphonate22 (13) under Horner-Wadsworth-Emmons (HWE) conditions gave the protected stilbene 14. After deprotection of the silyl ether 14 to the free alcohol 15, a three-step procedure was used to convert the benzyl alcohol to the corresponding phosphonate 16 through the intermediate mesylate and iodide. An HWE condensation of phosphonate 16 with the known aldehyde 179, 13 proceeded smoothly to afford the bis-stilbene 18. Hydrolysis of the methoxymethyl (MOM) acetals upon treatment with TsOH in methanol provided the target bis-stilbene 19.
Scheme 1.
Synthesis of the bis-stilbene 19.
Unfortunately, compound 19 discolored quickly and undergoes decomposition upon storage. This tendency for decomposition has been observed with other schweinfurthin analogues, and had been attributed to the presence of the resorcinol substructure. Previous work has shown that at least one phenolic group was important to the differential activity of the schweinfurthins in the 60 cell-line screen.14 Several analogs with one resorcinol oxygen present as a methyl ether have been prepared, and this substitution has been shown to retain potent and specific activity in the schweinfurthin F series.11 Therefore, preparation of a bis-stilbene with a D-ring mono methyl ether became attractive.
Synthesis of the desired mono methyl ether began with the known benzylic alcohol 20 (Scheme 2). Directed ortho metalation (DoM)23 followed by treatment of the intermediate anion with DMF afforded the desired aldehyde 21 in modest yield. While this DoM reaction is lower yielding than the halogen-metal exchange approach used in our previous work,16 this strategy allows more facile access to the desired aldehyde. Compound 20 and its precursors have more favorable solubility properties than the brominated intermediates required for synthesis of aldehyde 12, the DoM approach provides only starting material and product, and the DoM strategy can be performed without protecting the benzylic alcohol. Treatment of aldehyde 21 with phosphonate 13 and base gave the benzylic alcohol 22 in excellent yield. Application of the st andard 3-step procedure for conversion of the alcohol to the phosphonate afforded compound 23. Use of DMF as the solvent for the final Arbuzov reaction in this sequence greatly improves the yield.
Scheme 2.
Preparation of p-nitro and p-amino bis-stilbenes.
Preparation of phosphonate 23 set the stage for synthesis of the O-methyl analogue of nitro-stilbene 19. Condensation of phosphonate 23 with aldehyde 17 afforded the protected schweinfurthin 24 in good yield. Removal of the single MOM protecting group afforded the 5′-O-methyl analogue 25 in excellent yield. This compound displayed only slightly diminished activity relative to the parent resorcinol (vide infra) and, more importantly, demonstrated much improved stability.
With the key problems presented by compound 11 and 19 addressed, it was possible to prepare further analogues that could be utilized to probe the mechanism of schweinfurthin activity. The p-nitro stilbene 25 could, in principle, be used to identify the sub-cellular localization of the schweinfurthins. For such experiments to be truly informative however, a control compound with similar fluorescent properties but lacking the essential pharmacophore would be very helpful. Reduction of the nitro group would allow entrée to amine analogues which would vary the electronic properties of the bis-stilbenes and provide a site for further SAR studies. Rounding out the set of desired compounds would be the amine analogue of the control compound, along with the nitro- and amine-containing compounds based on the newly available schweinfurthin B A-ring diol system.9 These considerations led to identification of stilbene 35 as a target with potentially greater activity, to stilbenes 30 and 32 as relatively inactive but fluorescent controls, and to stilbenes 27 and 37 as amine-substituted targets.
The synthesis of these additional analogues was relatively straightforward. Condensation of the phosphonate 23 with the known aldehydes 28 and 33 gave the protected stilbenes 29 and 34. Hydrolysis of the MOM acetal of each of the nitro compounds 29 and 34 afforded the targets 30 and 35 in good yields. Reduction of the nitro groups of compounds 24, 29, and 34 with Zn0 in ammonium chloride24 afforded the desired amines 26, 31, and 36. Deprotection of these compounds under standard conditions was uneventful, leading to compounds 27, 32, and 37. This strategy provided the target compounds in excess of 95% chemical purity, with the exception of compound 37 (93%), and greater than 95% enantiomeric purity.
All of the target compounds exhibited significant fluorescence. The nitro compounds typically had an absorption maximum of about 430 nm and an emission maximum of ~575 nm, while the amines exhibited absorption maxima of 375 and typically had emission maxima ~495. Thus the nitro compounds 19, 25, 30, and 35 displayed larger Stokes shifts (~150 nm) vis-a-vis the amines 27, 32 and 37 (~120 nm). Of greater significance to the cellular localization studies, the nitro substituted compounds also demonstrate significantly red-shifted absorption and emission maxima compared to the previously synthesized bis-stilbene 11. This shift in fluorescence emission allowed cellular studies on these compounds without interference from autofluroescence.25 The fluorescence maxima of the amines is not shifted as greatly, but the utility of the nitro compounds may render this a moot point.
3. Biological Results and Discussion
The anti-cancer activities of many natural and synthetic schweinfurthins have been evaluated in the National Cancer Institute’s 60 cell-line screen. Because there often is a long waiting time for this assay, we have described a two-cell line screen comprised of a sensitive (SF-295) and moderately insensitive (A549) cell line.17 The two cell-line assay measures schweinfurthin-like activity and is comparable to the discrimination yielded by the NCI 60 cell screen.17 The schweinfurthin analogues, compounds 19, 25, 27, 35, and 37, display potent effects on MTT activity in SF-295 cells after 48 hours of treatment (Table 1). In this assay, SF-295 cells are especially sensitive to the nitro bis-stilbene compounds 19, 25, and 35, which have ED50 values of 0.05, 0.1, and 0.04 μM, respectively. The amine bis-stilbene compounds 27 and 37 display similar ED50 values. As expected, compounds 30 and 32 lacking the hexahydroxanthene structure display greatly diminished activity in comparison to the other schweinfurthin analogues (Table 1). Consistent with the natural schweinfurthins, the fluorescent analogues (19, 25, 27, 35, and 37) display decreased activity against the A549 cells in comparison to the SF-295 cells. The nitro bis-stilbenes are at least as potent in comparison to the amine bis-stilbenes. Control compounds 30 and 32 do not alter A549 MTT activity at concentrations as high as 10 μM.
Table 1.
The ED50 values for schweinfurthin analogues 19, 25, 27, 30, 32, 35, and 37 in the SF-295 and A549 cells at 48 hours, as measured by the MTT a ssay.
ED50 Values (μM) | ||
---|---|---|
Compound | SF-295 | A549 |
19 | 0.05 | 0.8 |
25 | 0.1 | 2.7 |
27 | 0.4 | 3.0 |
30 | >1 | >10 |
32 | >1 | >10 |
35 | 0.04 | 0.7 |
37 | 0.02 | 3.2 |
The fluorescent schweinfurthins may serve as probes for intracellular localization. Indeed, compound 25 displays peri-nuclear localization with distinct peripheral puncta, as demonstrated in Figure 2 (A-D). In comparison, compound 30, which lacks schweinfurthin-like activity at concentrations tested, localizes extensively in the peri-nuclear nuclear region with minimal diffuse fluorescence in the periphery of the cell shown in Figure 2 (E-H). Based on the difference in activity and localization, the peripheral fluorescence displayed by compound 25 may identify the schweinfurthin site(s) of action. Although the active analogue is more dispersed to peripheral regions of the cell than is the less active control compound, it remains to be determined whether this identifies a binding target that is itself peripheral or a mislocalized perinuclear target.
Figure 2.
The intracellular localization of compound 25 and 30. SF-295 cells were treated with compound 25 (500 nM) (A-D) or compound 30 (500 nM) (E-H) for 24 hours. Images depict intracellular localization of compound 25 (A) or compound 30 (E) alone, nuclear labeling of treated cell with DAPI (B and F), merged images of DAPI with compound 25 (C) or compound 30 (G), or fluorescence brightness distribution images of compound 25 (D) or 30 (H).
4. Conclusions
The synthesis of a small set of fluorescent analogues based on the schweinfurthins has been accomplished. Data obtained from our two-cell line screen supports our prior observations that one of the phenol groups of the right half of the molecule can be replaced with a methyl ether without great loss of activity and with a contemporaneous increase in stability. In addition, compounds with the A-ring diol (35 and 37) are slightly more potent than the corresponding 3-deoxy compounds (25 and 27) in the SF-295 cells. Importantly, compounds 19, 25, 27, 35, and 37 retain the potency and differential activity displayed by the natural schweinfurthins. Due to these characteristics and their fluorescent properties, these compounds can be utilized as intracellular probes for sites of schweinfurthin activity. Microscopic examination of the fluorescence from compound 25 demonstrates that localization is both peri-nuclear and peripheral. The peripheral localization of 25 is unique when compared to the relatively inactive compound 30; therefore, these sites may label the target of schweinfurthin activity. Based on puncta and dispersed nature of the observed fluorescence, compound 25 may localize in lysosomes or bind to protein(s) involved in trafficking. These possibilities will be investigated and described in due course.
5. Experimental Procedures and Methods
5.1 Protected Stilbene 14
A suspension of NaH (109 mg, 2.6 mmol, 60% in oil), and 15-crown-5 (1 drop) in THF was cooled to 0 °C. To this was added aldehyde 12 (245 mg, 0.66 mmol) and the known phosphonate 13 (181 mg, 0.66 mmol) in THF (1.5 mL). After the mixture was allowed to stir for 45 min, water was added dropwise and the solution was extracted with EtOAc. The resulting organic phase was washed with brine, dried (MgSO4), and concentrated in vacuo. Final purification by column chromatography (2:1 hexanes:EtOAc) gave the stilbene 14 (197 mg, 61%) as a bright yellow oil: 1H NMR δ 8.21–8.18 (m, 2H), 7.65 – 7.62 (m, 4H), 6.88 (s, 2H), 5.30 (s, 4H), 4.74 (s, 2H), 3.53 (s, 6H), 0.98 (s, 9H), 0.13 (s, 6H); 13C NMR δ 156.4 (2C), 146.1, 145.9, 143.8, 129.5, 126.4 (2C), 124.7, 123.9 (2C), 113.9, 105.6 (2C), 94.7 (2C), 64.5, 56.1 (2C), 25.7 (3C), 18.2, −5.4 (2C); HRMS (EI) calcd for C25H35NO7Si (M+) 489.2183 found 489.2173.
5.2 Benzylic alcohol 15
Silyl ether 14 (155 mg, 0.32 mmol) was dissolved in THF and the solution was cooled to 0 °C. To this solution was added TBAF (0.4 mL, 1.00 M in THF), and after 4 h the reaction was quenched by addition of NH4Cl (sat.). After extraction with EtOAc, the combined organic extracts were washed with water and brine, dried (MgSO4), and concentrated in vacuo to give the desired benzylic alcohol 15 (120 mg, 100%) as a clear oil: 1H NMR ((CD3)2CO δ 8.25–8.21(m 2H), 7.80 – 7.77 (m, 4H), 6.92 (s, 2H), 5.35 (s, 4H), 4.66 (d, J = 5.4 Hz, 2H), 4.43 (t, J = 5.4 Hz, 1H), 3.51 (s, 6H); 13C NMR ((CD3)2CO) δ 157.2 (2C), 146.9, 145.5, 130.0, 127.2 (2C), 125.3, 124.5 (2C), 114.4, 106.6 (2C), 100.5, 95.1 (2C), 64.1, 56.2 (2C); HRMS (EI) calcd for C19H21NO7 (M+) 375.1318 found 375.1315.
5.3 Phosphonate 16
Methanesulfonyl chloride (0.04 mL, 0.52 mmol) was added to a solution of benzylic alcohol 15 (120 mg, 0.32 mmol) and Et3N (0.2 mL 1.4 mmol) in THF at 0 °C. The reaction mixture was allowed to warm to room temperature over 1 h, quenched by addition of H2O, and extracted with EtOAc. The combined organic layers were washed with NH4Cl (sat.) and brine, dried (MgSO4), and concentrated in vacuo. The resulting residue and NaI (119 mg, 0.80 mmol) were stirred in acetone (10 mL) for 8 h. The reaction mixture was concentrated in vacuo to afford a red solid, which was dissolved in EtOAc. After the resulting yellow solution was washed with Na2S2O3 until the color faded, it was washed with brine, dried (MgSO4), and concentrated in vacuo. The resulting yellow oil was added to triethyl phosphite (2 mL) and toluene (2 mL) the reaction mixture was heated at 110 °C for 24 h. After the solution was allowed to cool to rt, the excess phosphite was removed at high vacuum. The initial orange/red oil was purified by flash chromatography (1:2 hexanes:EtOAc to 100% EtOAc) to afford phosphonate 16 (99 mg, 88%) as an orange oil: 1H NMR δ 8.21 – 8.18 (m, 2H), 7.64 – 7.61 (m, 4H), 6.81 – 6.80 (m, 2H), 5.28 (s, 4H), 4.07 (m, 4H), 3.52 (s, 6H), 3.13 (d, JHP = 22 Hz, 2H), 1.29 (t, J = 7.0 Hz, 6H); 13C NMR δ 156.4 (d, JCP = 3.9 Hz, 2C), 146.4, 145.8, 133.6 (d, JCP = 9.2 Hz), 129.7, 126.6 (2C), 124.4, 124.0 (2C), 114.2 (d, JCP = 3.6 Hz), 109.9 (d, JCP = 6.2 Hz, 2C), 94.7 (2C), 62.2 (d, JCP = 6.7 Hz, 2C), 56.4 (2C), 34.0 (d, JCP = 138 Hz), 16.4 (d, JCP = 6.3 Hz, 2C); 31P NMR δ 26.3; HRMS (EI) calcd for C23H30NO9P (M+) 495.1658 found 495.1656
5.4 Protected nitro stilbene 18
A suspension of NaH (60 mg, 1.5 mmol, 60% in oil), and 15-crown-5 (1 drop) in THF (5 mL) was cooled to 0 °C. To this mixture was added a solution of aldehyde 17 (17 mg, 0.06 mmol) and phosphonate 15 (28 mg, 0.06 mmol) in THF (1 mL). The resulting mixture was allowed to warm to rt and stirred a total of 6 hr. After water was added dropwise, the solution was extracted with EtOAc. The resulting organic phase was washed with brine, dried (MgSO4), and concentrated in vacuo. Final purification by column chromatography (3:1 to 1:1 hexanes:EtOAc) gave the stilbene 18 (23 mg, 59%) as an orange oil: 1H NMR δ 8.21 (d, J = 8.3 Hz, 2H), 7.66 (s, 2H), 7.65 (d, J = 8.3 Hz, 2H), 7.07 – 7.01 (m, 3H), 6.93 – 6.87 (m, 3H), 5.35 (s, 4H), 3.92 (s, 3H), 3.57 (s, 6H), 3.48 – 3.43 (m, 1H), 2.75 – 2.72 (m, 2H), 2.20 – 2.13 (m, 1H), 1.92 – 1.82 (m, 2H), 1.76 – 1.60 (m, 3H), 1.28 (s, 3H), 1.12 (s, 3H), 0.91 (s, 3H); 13C NMR δ 156.8 (2C), 149.0, 146.3, 146.0, 143.0, 139.3, 129.9, 129.7, 128.5, 126.6 (2C), 125.7, 124.6, 124.0 (2C), 122.6, 121.0, 114.6, 106.9, 106.1 (2C), 94.8 (2C), 77.9, 77.2, 56.4 (2C), 56.0, 46.7, 38.4, 37.6, 28.1, 27.2, 23.1, 19.9, 14.3; HRMS (EI) calcd for C37H43NO9 (M+) 645.2938 found 645.2952.
5.5 Nitro stilbene 19
To a solution of protected stilbene 18 (20 mg, 0.03 mmol) in MeOH was added pTsOH (30 mg, 0.17 mmol), and the resulting solution was stirred at rt for 6 hr. The reaction was quenched by addition of sat. NaHCO3, extracted with EtOAc, and the organic phase was washed with brine and dried (MgSO4). Concentration in vacuo, followed by final purification by column chromatography (2:1 to 1:1 hexanes:EtOAc) afforded the bis-stilbene 19 (12 mg, 78%) as a slightly yellow oil: UV (EtOH) λmax (log ε) 426 (4.42); λem 593; 1H NMR ((CD3)2CO) δ 9.06 (s, 2H), 7.05 – 6.78 (m, 6H), 3.78 (s, 3H), 3.40 – 3.35 (m, 1H), 2.71 – 2.68 (m, 2H), 1.82 – 1.58 (m, 6H), 1.18 (s, 3H), 1.09 (s, 3H), 0.87 (s, 3H); 13C NMR ((CD3)2CO) δ 158.6 (2C), 150.0, 147.7, 146.7, 144.1, 140.2, 130.5, 129.5, 128.5, 127.2 (2C), 126.7, 126.3, 124.7 (2C), 123.6, 121.9, 111.7, 108.2, 105.9 (2C), 77.7, 77.5, 56.0, 55.4, 47.7, 39.0, 38.6, 27.8, 23.7, 20.3, 14.8; HRMS (EI) calcd for C33H35O7N (M+) 557.2414 found 557.2422.
5.6 Aldehyde 21
To a solution of the alcohol 20 (0.45 g, 2.3 mmol) in THF at 0 °C(194 mg, 43%): 1H NMR δ 10.4 (s, 1H), 6.74 (s, 1H), 6.65 (s, 1H), 5.25 (s, 2H), 4.69 (s, 2H), 3.82 (s, 3H), 3.49 (s, 3H), 3.03 (br s, 1H); 13C NMR δ 189.1, 162.0, 159.9, 150.4, 113.7, 104.7, 102.5, 94.6, 64.5, 56.5, 55.9. Anal. Calcd for C11H14O5: C, 58.40; H, 6.24. Found: C, 58.69; H, 6.32. was added n-BuLi (2.8 mL, 2.0 M in hexanes) dropwise over 1 min. After 25 min, the solution was cooled to −30 °C and DMF (0.23 mL, 3.0 mmol, containing some CaH2 as a drying agent) was added. The reaction was allowed to progress for an additional 1 hr, and then quenched by addition of NH4Cl (sat.). After the aqueous phase was extracted with EtOAc, the combined organic phases were washed with brine, dried (MgSO4), and concentrated in vacuo to afford a yellow oil. Final purification by column chromatography (2:1 to 1:2 hexanes:EtOAc) afforded aldehyde 21 (192 mg, 37%) as a clear oil, along with a significant amount of recovered starting material
5.7 Benzyl Alcohol 22
To a solution of aldehyde 21 (128 mg, 0.57 mmol) in THF (12 mL) at rt was added 15-crown-5 (0.01 mL), diethyl 4-nitrobenzylphosphonate (13, 203 mg, 0.74 mmol), followed by NaH (220 mg, 5.5 mmol, 60% in oil), which resulted in the rapid appearance of a maroon color. After 8 min, the reaction was quenched by slow addition of water. The resulting solution was extracted with EtOAc, and the combined organic phases were washed with brine, dried (MgSO4), and concentrated in vacuo. Final purification by column chromatography (6:4 hexanes/THF) afforded compound 22 (191 mg, 98%) as an orange solid: 1H NMR δ 8.20 – 8.18 (m, 2H), 7.64 – 7.61 (m, 4H), 6.80 (s, 1H), 6.69 (s, 1H), 5.29 (s, 2H), 4.70 (s, 2H), 3.94 (s, 3H), 3.53 (s, 3H); 13C NMR δ 159.2, 156.6, 145.9, 142.9, 129.8, 126.6 (2C), 124.5, 124.3, 124.0 (2C), 113.8, 105.5, 103.1, 94.8, 65.2, 56.4, 55.8; HRMS (EI) calcd for C18H19NO6 (M+) 345.1212 found 345.1216.
5.8 Phosphonate 23
To a solution of benzyl alcohol 22 (193 mg, 0.56 mmol) in THF at rt was added TEA (0.2 mL, 1.4 mmol) followed by MsCl (0.1 mL, 1.3 mmol). After 50 min, the reaction was quenched by addition of water. The resulting solution was extracted with EtOAc, washed with brine, dried (MgSO4), and concentrated in vacuo. This material was used immediately without further purification. The residue from the above step was dissolved in anhydrous acetone (8 mL) and NaI (210 mg, 1.4 mmol) was added at rt in the dark. After 1 h, the reaction was quenched by addition of water, the resulting solution was extracted with EtOAc, and was washed with brine. The organic phase was dried (MgSO4) and concentrated in vacuo in the dark. This material was used immediately in the next step without further purification. The residue from the above step was dissolved in DMF (3 mL), P(OEt)3 (0.4 mL, 2.3 mmol) was added, and the mixture was heated to 115 °C. After 17 h, an additional portion of P(OEt)3 (0.4 mL, 2.3 mmol) was added. The reaction was allowed to cool to rt after an additional 3.5 h and concentrated in vacuo. Final purification by column chromatography (1% MeOH, 20% hexanes, 79% EtOAc) afforded the desired phosphonate 23 (245 mg, 95% over 3 steps) as a bright yellow oil: 1H NMR δ 8.20 – 8.17 (m, 2H), 7.63 – 7.61 (m, 4H), 6.75 (s, 1H), 6.63 (s, 1H), 5.27 (s, 2H), 4.11 – 4.01 (m, 4H), 3.92 (s, 3H), 3.51 (s, 3H), 3.13 (d, JHP = 22 Hz, 2H), 1.28 (t, J = 7.1 Hz, 6H); 13C NMR δ 158.8 (d, JCP = 3.8 Hz), 156.4 (d, JCP = 3.4 Hz), 146.3, 146.0, 133.5 (d, JCP = 9.1 Hz), 129.7, 126.6 (2C), 124.5 (d, JCP = 1.8 Hz), 124.0 (2C), 123.0, 109.1 (d, JCP = 7.1 Hz), 106.5 (d, JCP = 6.6 Hz), 94.9, 62.2, 62.1, 56.1 (d, JCP = 34 Hz, 2C), 34.5 (d, JCP = 138 Hz), 16.4 (d, JCP = 6.0 Hz, 2C); 31P NMR δ 26.3; HRMS (EI) calcd for C22H28NO8P (M+) 465.1553 found 465.1552.
5.9 Protected stilbene 24
To a solution of aldehyde 17 (80 mg, 0.26 mmol) and phosphonate 23 (100 mg, 0.25 mmol) in THF at rt was added 15-crown-5 (0.01 mL) followed by NaH (63 mg, 1.6 mmol, 60% in oil), and after 75 min the reaction was quenched by addition of water. The resulting solution was extracted with EtOAc and the combined organic phases were washed with brine. After the organic phase was dried (MgSO4) and concentrated in vacuo, final purification by column chromatography (1:1 hexanes/EtOAc) afforded recovered phosphonate 23 (12 mg, 12%) and compound 24 (94 mg, 71%) as an orange solid: 1H NMR δ 8.22 – 8.18 (m, 2H), 7.67 – 7.63 (m, 4H), 7.09 – 7.04 (m, 1H), 6.97 – 6.90 (m, 4H), 6.78 – 6.74 (m, 1H), 5.36 (s, 2H), 4.00 (s, 3H), 3.92 (s, 3H), 3.58 (s, 3H), 3.48 – 3.44 (m, 1H), 2.78 – 2.73 (m, 2H), 2.19 – 2.13 (m, 1H), 1.92 – 1.82 (m, 2H), 1.73 – 1.54 (m, 3H), 1.28 (s, 3H), 1.13 (s, 3H), 0.91 (s, 3H); 13C NMR δ 159.1, 156.8, 149.0, 146.2, 146.1, 143.0, 139.1, 129.8, 129.4, 128.4, 126.5 (2C), 125.8, 124.6, 124.0 (2C), 122.7, 120.9, 113.8, 106.9, 105.4, 102.4, 94.8, 77.9, 77.2, 56.4, 56.0, 55.8, 46.7, 38.4, 37.6, 28.2, 27.3, 23.1, 19.8, 14.3; HRMS (EI) calcd for C36H41NO8 (M+) 615.2832, found 615.2837.
5.10 Nitro schweinfurthin 25
To a solution of compound 24 (16 mg, 0.03 mmol), in CH3OH (2.5 mL) and EtOAc (0.5 mL) was added TsOH·H2O (32 mg, 0.16 mmol). After 24 h, the reaction was quenched by addition of NaHCO3 and concentrated in vacuo. The resulting solution was extracted with EtOAc, and the combined organic phase was washed with brine, dried (MgSO4), and concentrated in vacuo. Final purification by column chromatography (1:1 hexanes/EtOAc) afforded compound 25 (13 mg, 85%) as a dark orange solid: UV (EtOH) λmax (log ε) 429 (4.25); λem 557; 1H NMR δ 8.20 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 16.8 Hz, 1H), 7.54 (d, J = 16.8 Hz, 1H), 7.01 (d, J = 16.0 Hz, 1H), 6.89 (s, 1H), 6.88 (s, 1H), 6.85 (d, J = 16.0 Hz, 1H), 6.65 (s, 1H), 6.63 (s, 1H), 5.50 (br d, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.46 – 3.44 (m, 1H), 2.75 – 2.72 (m, 2H), 2.17 – 2.14 (m, 2H), 1.90 – 1.69 (m, 4H), 1.27 (s, 3H), 1.11 (s, 3H), 0.90 (s, 3H); 13C NMR δ 159.2, 155.0, 149.0, 146.3, 145.5, 143.1, 139.1, 129.9, 129.2, 128.4, 126.6 (2C), 125.4, 124.8 124.0 (2C), 122.7, 120.9, 111.8, 106.9, 106.5, 101.5, 78.0, 77.7, 56.0, 55.8, 46.7, 38.4, 37.6, 28.3, 27.3, 23.1, 19.9, 14.3; HRMS (ESI) m/z calcd for C34H37NO7 (M+) 571.2570, found 571.2567.
5.11 Protected amine 26
To a solution of compound 24 (33 mg, 0.05 mmol) in acetone (3 mL) was added NH4Cl (sat., 1 mL) followed by Zn0 dust (67 mg, 1.0 mmol) and the mixture was heated to reflux. After 70 min, the solution was allowed to cool and decanted into a separatory funnel. The resulting solution was extracted with EtOAc, and the combined organic phases were washed with brine, dried (MgSO4), and concentrated in vacuo. Final purification by column chromatography (4:6 hexanes/EtOAc to 99:1 EtOAc/MeOH) afforded amine 26 (25 mg, 80%) as an orange oil: 1H NMR δ 7.51 (d, J = 16.4 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 16.4 Hz, 1H), 7.01 (d, J = 16.4 Hz, 1H), 6.92 – 6.88 (m, 4H), 6.76 (d, J = 0.8 Hz, 1H), 6.67 (d, J = 8.0 Hz, 2H), 5.30 (s, 2H), 3.94 (s, 3H), 3.90 (s, 3H), 3.54 (s, 3H), 3.42 (dd, J = 11.8, 4.0 Hz, 1H), 2.72 (m, 2H), 2.16 – 2.11 (m, 1H), 1.88 – 1.81 (m, 3H), 1.73 – 1.60 (m, 2H), 1.25 (s, 3H), 1.10 (s, 3H), 0.89 (s, 3H); 13C NMR δ 158.4, 156.0, 148.9, 145.6, 142.6, 136.8, 132.4, 129.9, 128.7, 128.5, 127.5 (2C), 126.2, 122.6, 120.6, 116.3, 115.7, 115.1 (2C), 106.7, 105.9, 102.7, 94.9, 77.9, 77.0, 56.2, 55.9, 55.7, 46.7, 38.3, 37.6, 28.2, 27.3, 23.1, 19.8, 14.3; HRMS (ESI) m/z calcd for C36H43NO6 (M+) 585.3090, found 585.3088.
5.12 Amine 27
To a solution of amine 26 (22 mg, 0.036 mmol), in CH3OH (2 mL) and EtOAc (0.5 mL) was added TsOH·H2O (43 mg, 0.13 mmol). After 23 h, the reaction was quenched by addition of NaHCO3 and concentrated in vacuo. The resulting solution was extracted with EtOAc, and the combined organic phases were washed with brine. The organic phase was dried (MgSO4) and concentrated in vacuo. This afforded schweinfurthin 26 (20 mg, 100%) without further purification as a dark orange solid: UV (EtOH) λmax (log ε) 377 (4.53); λem 493; 1H NMR δ 7.33 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 16.8 Hz, 1H), 7.12 (d, J = 16.8 Hz, 1H), 6.95 (d, J = 16.8 Hz, 1H), 6.87 – 6.81 (m, 3H), 6.67 – 6.65 (m, 3H), 6.59 (s, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.41 (dd, J = 11.8, 3.4 Hz, 1H), 2.71 (m, 2H), 2.14 – 2.10 (m, 1H), 1.87 – 1.83 (m, 2H), 1.71 – 1.58 (m, 2H), 1.24 (s, 3H), 1.09 (s, 3H), 0.87 (s, 3H); 13C NMR δ 159.5, 155.6, 150.0, 147.0, 143.8, 138.4, 133.3, 130.1, 129.9, 129.8, 128.7 (2C), 127.3, 123.8, 121.8, 117.9, 116.3 (2C), 114.4, 108.1, 107.7, 102.2, 79.0, 78.2, 57.1, 56.8, 47.8, 39.4, 38.7, 29.3, 28.4, 24.2, 20.9, 15.3; HRMS (ESI) m/z calcd for C34H39NO5 (M+) 541.2828, found 541.2835.
5.13 Stilbene 29
To a solution of 3,4-dimethoxybenzaldehyde (28, 50 mg, 0.26 mmol) and phosphonate 23 (100 mg, 0.25 mmol) in THF (4 mL) at rt was added 15-crown-5 (0.01 mL) followed by NaH (57 mg, 1.4 mmol, 60% in oil), and after 65 min the reaction was quenched by addition of water. The resulting solution was extracted with EtOAc, and the combined organic phases were washed with brine. The organic phase was dried (MgSO4) and concentrated in vacuo. Final purification by column chromatography (3:1 hexanes/EtOAc to EtOAc) afforded recovered phosphonate 23 (27 mg, 27%) and compound 29 (94 mg, 71%) as an orange solid: 1H NMR δ 8.19 (d, J = 8.8 Hz, 2H), 7.66 (s, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.11 – 7.07 (m, 3H), 6.96 (s, 1H), 6.96 (s, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.78 (s, 1H), 5.34 (s, 2H), 3.99 (s, 3H), 3.96 (s, 3H), 3.91 (s, 3H), 3.56 (s, 3H); 13C NMR δ 159.1, 156.8, 149.1, 149.0, 146.1, 146.1, 138.9, 129.9, 129.5, 129.5, 126.6 (2C), 126.3, 124.6, 124.0 (2C), 120.2, 113.9, 111.1, 108.5, 105.4, 102.4, 94.8, 56.4, 55.9, 55.8, 55.7; HRMS (ESI) m/z calcd for C27H27NO7 (M+) 477.1788, found 477.1771.
5.14 Compound 30
To a solution of compound 29 (20 mg, 0.042 mmol), in CH3OH (4 mL) and EtOAc (2 mL) was added TsOH·H2O (54 mg, 0.28 mmol) and the solution was stirred at rt. After 18.5 h, the reaction was quenched by addition of NaHCO3 and concentrated in vacuo. The resulting solution was extracted with EtOAc, and the combined organic phases were washed with brine. After the organic phase was dried (MgSO4) and concentrated in vacuo, final purification by column chromatography (6:4 hexanes/EtOAc to 4:6 hexanes/EtOAc) afforded compound 30 (16 mg, 88%) as a dark orange solid: UV (EtOH) λmax (log ε) 431 (4.39); λem 579; 1H NMR ((CD3)2CO) δ 8.22 (d, J = 9.2 Hz, 2H), 7.81 (s, 2H), 7.76 (d, J = 9.2 Hz, 2H), 7.25 (d, J = 2.0 Hz, 1H), 7.19 (d, J = 16.0 Hz, 1H), 7.00 (dd, J = 8.4, 2.0 Hz, 1H), 7.04 (d, J = 16.4 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 1.2 Hz, 1H), 6.81 (d, J = 1.2 Hz, 1H), 4.00 (s, 3H), 3.87 (s, 3H), 3.83 (3H); 13C NMR ((CD3)2CO) δ 160.5, 158.1, 150.7, 150.6, 147.4, 147.1, 140.3, 131.2, 130.3, 129.3, 127.4 (2C), 127.1, 126.0, 124.8 (2C), 121.1, 112.7, 110.4, 107.6, 104.5, 101.5, 56.2, 56.1, 56.1; HRMS (ESI) m/z calcd for C25H23NO6 (M+) 433.1525, found 433.1522.
5.15 Compound 31
According to the procedure described for compound 26, compound 29 (20 mg, 0.04 mmol), NH4Cl (sat., 1 mL), and Zn0 dust (30 mg, 0.46 mmol) gave after final purification by column chromatography (4:6 hexanes/EtOAc) amine 31 (12 mg, 67%) as orange solid: 1H NMR δ 7.53 (d, J = 16.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 16.8 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.06 (dd, J = 8.4, 2.0 Hz, 1H), 7.04 (d, J = 16.4 Hz, 1H), 6.94 (d, J = 1.2 Hz, 1H), 6.93 (d, J = 16.4 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 0.8 Hz, 1H), 6.68 (d, J = 8.4 Hz, 2H), 5.31 (s, 2H), 3.96 (s, 3H), 3.95 (s, 3H), 3.91 (s, 3H), 3.55 (s, 3H); 13C NMR δ 158.4, 156.0, 149.0, 148.9, 145.7, 136.6, 132.5, 130.3, 129.9, 128.3, 127.6 (2C), 126.8, 119.9, 116.3, 115.8, 115.2 (2C), 111.1, 108.5, 106.0, 102.7, 94.9, 56.3, 55.9, 55.8, 55.7; HRMS (ESI) m/z calcd for C27H29NO5 (M+) 447.0246, found 447.2051.
5.16 Compound 32
According to the procedure described for compound 30, compound 31 (10 mg, 0.02 mmol), in CH3OH and EtOAc was treated with TsOH·H2O (60 mg, 0.31 mmol), and after final purification by column chromatography (4:6 hexanes/EtOAc) afforded compound 32 (8 mg, 89%) as a dark orange solid: UV (EtOH) λmax (log ε) 377 (4.63); λem 512; 1H NMR ((CD3)2CO) δ 7.56 (d, J = 16.8 Hz, 1H), 7.29 – 7.22 (m, 3H), 7.10 – 6.92 (m, 6H), 6.76 (d, J = 2.8 Hz, 1H), 6.65 (d, J = 8.4 Hz, 2H), 4.69 (brd, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.81 (s, 3H); 13C NMR ((CD3)2CO) δ 159.6, 156.9, 150.6, 150.4, 148.7, 137.6, 132.8, 131.5, 129.3, 128.9, 128.0 (2C), 127.5, 120.8, 116.4, 115.3 (2C), 112.8, 110.3, 107.7, 104.5, 101.6, 56.1, 56.1, 56.0; HRMS (ESI) m/z calcd for C25H25NO4 (M+) 403.1784, found 403.1779.
5.17 Compound 34
To a solution of aldehyde 33 (25 mg, 0.07 mmol) and phosphonate 23 (50 mg, 0.11 mmol) in THF (4 mL) at rt was added 15-crown-5 (0.01 mL) followed by NaH (51 mg, 1.3 mmol, 60% in oil). After 35 min, the reaction was quenched by addition of water. The resulting solution was extracted with EtOAc, washed with brine, dried (MgSO4) and concentrated in vacuo. Final purification by column chromatography (4:6 hexanes/EtOAc) afforded compound 34 (36 mg, 78%) as an orange solid: 1H NMR δ 8.19 (d, J = 8.8 Hz, 2H), 7.66 – 7.62 (m, 4H), 7.06 (d, J = 16.4 Hz, 1H), 6.96 (s, 1H), 6.95 – 6.90 (m, 3H), 6.77 (s, 1H), 5.35 (s, 2H), 4.83 (d, J = 6.8 Hz, 1H), 4.73 (d, J = 6.8 Hz, 1H), 4.32 (ddd, J = 3.2, 3.2, 3.2 Hz, 1H), 3.99 (s, 3H), 3.92 (s, 3H), 3.57 (s, 3H), 3.47 (s, 3H), 3.28 (d, J = 3.6 Hz, 1H), 2.81 – 2.75 (m, 2H), 2.57 (dd, J = 14.2, 3.0 Hz, 1H), 2.34 (br d, 1H), 1.98 (dd, J = 14.0, 2.8 Hz, 1H), 1.80 (dd, J = 12.5, 5.2 Hz, 1H), 1.49 (s, 3H), 1.12 (s, 3H), 1.10 (s, 3H); 13C NMR δ 159.1, 156.8, 149.0, 146.1, 146.1, 142.6, 139.1, 129.8, 129.3, 128.4, 126.5 (2C), 125.8, 124.6, 124.0 (2C), 122.8, 120.8, 113.7, 106.8, 105.3, 102.4, 96.8, 94.8, 84.7, 76.6, 68.6, 56.3, 56.1, 55.9, 55.7, 47.0, 42.2, 37.8, 28.7, 22.9, 21.5, 16.6; HRMS (ESI) m/z calcd for C38H45NO10 (M+) 675.3043, found 675.3040.
5.18 Compound 35
According to the procedure for compound 30, compound 34 (16 mg, 0.024 mmol), in CH3OH and EtOAc was treated with TsOH·H2O (60 mg, 0.32 mmol) and after final purification by column chromatography (3:7 hexanes/EtOAc) afforded schweinfurthin 35 (10 mg, 71%) as a dark orange wax: 1H NMR δ 8.20 (d, J = 8.8 Hz, 2H), 7.67 – 7.61 (m, 3H), 7.55 (d, J = 16.4 Hz, 1H), 7.01 (d, J = 16.0 Hz, 1H), 6.89 (s, 1H), 6.88 (s, 1H), 6.85 (d, J = 16.0 Hz, 1H), 6.64 (s, 2H), 4.26 (ddd, J = 3.2, 3.2, 3.2 Hz, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 3.39 (d, J = 3.6 Hz, 1H), 2.82 – 2.76 (m, 2H), 2.52 (dd, J = 14.4, 2.8 Hz, 1H), 2.30 (dd, J = 14.4, 3.2 Hz, 1H), 1.79 (dd, J = 12.8, 5.2 Hz, 1H), 1.47 (s, 3H), 1.13, (s, 3H), 1.09 (s, 3H); 13C NMR δ 159.2, 155.3, 149.0, 146.2, 145.7, 142.6, 139.1, 129.8, 129.2, 128.4, 126.6 (2C), 125.5, 124.8, 124.0 (2C), 122.9, 120.9, 111.9, 107.0, 106.5, 101.4, 77.5, 76.8, 70.7, 56.0, 55.8, 46.8, 43.3, 38.0, 28.9, 23.0, 21.6, 16.0; HRMS (ESI) m/z calcd for C34H37NO8 (M+) 587.2519, found 587.2518.
5.19 Amine 36
According to the procedure described for compound 26, compound 35 (16 mg, 0.024 mmol), NH4Cl (sat., 1 mL) and Zn0 dust (26 mg, 0.4 mmol) gave after final purification by column chromatography (4:6 hexanes/EtOAc to 99:1 EtOAc/MeOH) amine 36 (12 mg, 80%) as an orange oil: 1H NMR δ 7.52 (d, J = 16.8 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 16.0 Hz, 1H), 7.01 (d, J = 16.0 Hz, 1H), 6.93 – 6.88 (m, 4H), 6.76 (s, 1H), 6.70 (d, 8.0 Hz, 2H), 5.30 (s, 2H), 4.84 (d, J = 6.8 Hz, 1H), 4.73 (d, J = 6.8 Hz, 1H), 4.32 (ddd, J = 2.8, 2.8, 2.8 Hz, 1H), 3.95 (s, 3H), 3.91 (s, 3H), 3.55 (s, 3H), 3.47 (s, 3H), 3.28 (d, J = 2.8 Hz, 1H), 2.84 – 2.71 (m, 2H), 2.57 (dd, J = 13.6, 2.4 Hz, 1H), 1.98 (dd, J = 11.2, 2.6 Hz, 1H), 1.80 (dd, J = 12.6, 5.0 Hz, 1H), 1.49 (s, 3H), 1.12 (s, 3H), 1.10 (s, 3H); 13C NMR δ 158.5, 156.1, 149.1, 145.2, 142.5, 136.9, 132.4, 130.4, 128.8, 128.7, 127.6 (2C), 126.3, 122.8, 120.6, 116.6, 115.8, 115.5 (2C), 107.0, 106.0, 102.8, 96.9, 95.0, 84.9, 76.5, 68.7, 56.3, 56.1, 56.0, 55.8, 47.2, 42.3, 37.9, 28.8, 23.0, 21.6, 16.7; HRMS (ESI) m/z calcd for C38H47NO8 (M+) 645.3302, found 645.3312.
5.20 Amine 37
According to the procedure for compound 30, compound 36 (11 mg, 0.017 mmol), in CH3OH was treated with TsOH·H2O (25 mg, 0.13 mmol), and gave after final purification by column chromatography (EtOAc) schweinfurthin 37 (9 mg, 95%) as a dark orange wax: UV (EtOH) λmax (log ε) 375 (4.63); λem 481; 1H NMR (CD3OD) δ 7.50 (d, J = 16.4 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 16.4 Hz, 1H), 7.01 – 6.88 (m, 4H), 6.69 (d, J = 8.4 Hz, 2H), 6.66 (d, J = 1.2 Hz, 1H), 6.64 (s, 1H), 4.14 (ddd, J = 3.6, 3.6, 3.6 Hz, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.30 (obscured by solvent, 1H), 2.78 – 2.76 (m, 2H), 2.35 (dd, J = 13.8, 3.0 Hz, 1H), 1.92 (dd, J = 13.4, 3.0 Hz, 1H), 1.73 (dd, J = 11.8, 6.2 Hz, 1H), 1.41 (s, 3H), 1.10 (s, 3H), 1.09 (s, 3H); 13C NMR (CD3OD) δ 160.1, 157.4, 150.3, 147.9, 143.6, 138.3, 131.3, 130.6, 129.5, 128.1 (2C), 127.4, 124.4, 122.0, 117.5, 116.7 (2C), 115.8, 114.6, 108.5, 107.5, 101.9 78.8, 78.1, 71.8, 56.5, 56.2, 48 (obscured by solvent), 44.8, 39.2, 29.4, 24.0, 22.0, 16.6; HRMS (ESI) m/z calcd for C34H39NO6 (M+) 557.2777, found 557.2784.
5.21 Cell culture
The SF-295 and A549 cell lines were purchased from the NCI and ATCC, respectively. These cell lines were maintained in RPMI 1640 (SF-295) or F-12 media (A549), each supplemented with 10% FBS, amphotericin B, penicillin/streptomycin, and L-glutamine. Cells were cultured in the presence of 5% CO2 at 37° C.
5.22 Cytotoxicity Assay
Either SF-295 or A549 cells were incubated with indicated concentrations of compounds 19, 25, 27, 32, 35, or 37. After 44 hours of exposure, media was aspirated and replaced with either RPMI 1640 lacking phenol Red (SF-295) or F-12 (A549) media containing MTT salt (Calbiochem, San Diego, CA). At the conclusion of the 48 hour interval, cells were solubilized in stop solution (10% 1 N HCl, 10% triton X-100, and isopropyl alcohol) overnight at room temperature. The absorption of the resulting solution was measured at 540 nm and 650 nm. The effective dose 50 concentrations were determined using Calcusyn software (Biosoft, Cambridge, UK).
5.23 Fluorescence microscopy
The SF-295 cells were plated on 22 × 22 mm coverslips. After reaching 45% confluency, cells were treated with indicated concentrations of compound 25 or 30 for 24 hours. At the conclusion of the treatment interval, cells were washed three times in PBS and fixed in 4% formaldehyde for 15 minutes. Coverslips were then washed in PBS three times and mounted in Vectashield containing DAPI. Compound and DAPI fluorescence was visualized using a Bio-Rad Multi-photon microscope. Images were processed with ImageJ. Images demonstrating brightness distribution were created with the fire look up table.
Supplementary Material
Acknowledgements
We thank the University of Iowa for a Shriner Fellowship (JJT). Financial support from the Roy J. Carver Charitable Trust and the National Cancer Institute (R41CA126020 via Terpenoid Therapeutics, Inc.) is gratefully acknowledged. The content is solely the responsibility of the authors, and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Supplementary Data
General experimental procedures, the 1H and 13C NMR spectra for compounds 14-16, 18, 19, 21-27, 29-32, 34-37, and a table of compound purity data, can be found here. This material is available free of charge via the Internet at:
References
- 1.Newman DJ, Cragg GM. J. Nat. Prod. 2007;70:461–477. doi: 10.1021/np068054v. [DOI] [PubMed] [Google Scholar]
- 2.Kingston DGI. J. Nat. Prod. 2000;63:726–734. doi: 10.1021/np000064n. [DOI] [PubMed] [Google Scholar]
- 3.Beutler JA, Shoemaker RH, Johnson T, Boyd MR. J. Nat. Prod. 1998;61:1509–1512. doi: 10.1021/np980208m. [DOI] [PubMed] [Google Scholar]
- 4.Beutler JA, Jato J, Cragg GM, Boyd MR. Nat. Prod. Lett. 2000;14:399–404. [Google Scholar]
- 5.Yoder BJ, Cao S, Norris A, Miller JS, Ratovoson F, Razafitsalama J, Andriantsiferana R, Rasamison VE, Kingston DGI. J. Nat. Prod. 2007;70:342–346. doi: 10.1021/np060484y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Thoison O, Hnawia E, Gueritte-Voegelein F, Sevenet T. Phytochemistry. 1992;31:1439–1442. [Google Scholar]
- 7.Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. J. Nat. Cancer Inst. 1989;81:1088–1092. doi: 10.1093/jnci/81.14.1088. [DOI] [PubMed] [Google Scholar]
- 8.a) Deng JZ, Newman DJ, Hecht SM. J. Nat. Prod. 2000;63:1269–1272. doi: 10.1021/np000084p. [DOI] [PubMed] [Google Scholar]; b) Zhou BN, Hoch JM, Johnson RK, Mattern MR, Eng WK, Ma J, Hecht SM, Newman DJ, Kingston DGI. J. Nat. Prod. 2000;63:1273–1276. doi: 10.1021/np000058r. [DOI] [PubMed] [Google Scholar]
- 9.Topczewski JJ, Neighbors JD, Wiemer DF. J. Org. Chem. 2009;74:6965–6972. doi: 10.1021/jo901161m. [DOI] [PubMed] [Google Scholar]
- 10.Treadwell EM, Cermak SC, Wiemer DF. J. Org. Chem. 1999;64:8718–8723. [Google Scholar]
- 11.Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Biorg. Med. Chem. Lett. 2007;17:911–915. doi: 10.1016/j.bmcl.2006.11.096. [DOI] [PubMed] [Google Scholar]
- 12.Mente NR, Neighbors JD, Wiemer DF. J. Org. Chem. 2008;73:7963–7970. doi: 10.1021/jo800951q. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.a) Neighbors JD, Beutler JA, Wiemer DF. J. Org. Chem. 2005;70:925–931. doi: 10.1021/jo048444r. [DOI] [PubMed] [Google Scholar]; b) Wiemer DF, Neighbors JD, Beutler JA. PCT Int. Appl. Preparation of Schweinfurthin analogues. 2005. CODEN: PIXXD2 WO 2005092878 A2 20051006 CAN 143:347317 AN 2005:1075787. [Google Scholar]
- 14.Neighbors JD, Salnikova MS, Beutler JA, Wiemer DF. Biorg. Med. Chem. 2006;14:1771–1784. doi: 10.1016/j.bmc.2005.10.025. [DOI] [PubMed] [Google Scholar]
- 15.Neighbors JD, Mente NR, Boss KD, Zehnder DW, II, Wiemer DF. Tetrahedron Lett. 2008;49:516–519. [Google Scholar]
- 16.Neighbors JD, Kuder CH, Hohl RJ, Wiemer DF. Biorg. Med. Chem. 2009;17:4718–4723. doi: 10.1016/j.bmc.2009.04.071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Bioorg. Med. Chem. 2010;18:1676–1683. doi: 10.1016/j.bmc.2009.12.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Neighbors JD, Topczewski JJ, Wiemer DF. Tetrahedron Lett. 2009;50:3881–3884. [Google Scholar]
- 19.Wiemer, David F, Neighbors, Jeffrey D, Hohl, Raymond J, Kuder Craig. Schweinfurthin analogs. PCT Int. Appl. 2009 56 pp. CODEN: PIXXD2 WO 2009158516 A1 20091230 CAN 152:119838 AN 2009:1618103. [Google Scholar]
- 20.Meier H. Angew. Chem. Int. Ed. Eng. 2005;44:2482–2506. doi: 10.1002/anie.200461146. [DOI] [PubMed] [Google Scholar]
- 21.Gompper R, Wagner HU. Angew. Chem. Int. Ed. Eng. 1988;27:1437–1455. [Google Scholar]
- 22.a) Kagan F, Birkenmeyer RD, Strube RE. J. Am. Chem. Soc. 1959;81:3026–3031. [Google Scholar]; b) Wadsworth DH, Schupp OE, III, Seus EJ, Ford JA., Jr. J. Org. Chem. 1965;30:680–685. [Google Scholar]
- 23.Neighbors JD, Salnikova MS, Wiemer DF. Tetrahedron Lett. 2005;46:1321–1324. [Google Scholar]
- 24.Miljanic S, Frkanec L, Meic Z, Zinic M. Langmuir. 2005;21:2754–2760. doi: 10.1021/la047183d. [DOI] [PubMed] [Google Scholar]
- 25.Schneckenburger H, Wagner M, Weber P, Strauss WSL, Sailer R. J. Fluoresc. 2004;14:649–654. doi: 10.1023/b:jofl.0000039351.09916.cc. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.